Antipsychotics (APPs) are one of the basic drug groups in psychiatry. APPs are used in the treatment of schizophrenia, psychotic disorders, as well as in the treatment of bipolar affective disorder, mainly its manic phase.
The aim of the study was to present the actual situation, regarding the registered therapeutic indications of APPs, admitted for turn in Poland.
The registered indications of different APPs’ market forms available in Poland, in the aspect of specific indications for the treatment of psychiatric disorders, as well as the differences in the description of specific indications of different market forms of the given drug were analyzed.
The analysis indicated the significant differences in registered therapeutic indications. The differences are also present within registrations of different market forms of the same neuroleptic. The registered indications of neuroleptics may significantly vary from the indications listed in psychiatry and pharmacotherapy textbooks. The differences reduce the possibility of use of LPPs in the treatment of psychiatric disorders, and force physicians to prescribe the concrete market form of a drug.
Authors suggest that a uniformed interpretation of the therapeutic indications of APPs, referred not to a market name but an international name of a drug, might improve the financial safety of psychiatrist’s work. Legislative changes, introducing possibilities of use of drugs on the basis of scientific evidence apart of the registered indication are obligatory. The changes ought to assure the legal safety both to the treating person and the treated one.